In breast cancer preclinical models, cells lacking PTEN acquire mesenchymal characteristics, as evidenced by the high levels of the mesenchymal marker vimentin and the loss of E-cadherin at adhesion sites, as well as by the increase of the EMT-inducing transcription factors Snail1, Slug, ZEB1, and Twist2 [61]. This evidence concerns the gene ZEB1 and breast cancer.